TAO WU to Risk Assessment
This is a "connection" page, showing publications TAO WU has written about Risk Assessment.
Connection Strength
0.041
-
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020 09; 95(9):1047-1056.
Score: 0.021
-
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. JAMA Netw Open. 2019 03 01; 2(3):e190194.
Score: 0.020